Boston Scientific estimates 2024 adjusted EPS of $2.38-$2.42 compared to prior guidance of $2.29-$2.34 and consensus of $2.33. For the third quarter, the company estimates net sales growth of 13%-14% on a reported and organic basis. The company forecasts adjusted EPS of $0.57-$0.59 versus a consensus of $0.57. Price Action: BSX stock was trading lower by 1.95% at $77.05 at the last check on Wednesday. Read Next: Photo via Shutterstock